Prediction of breast cancer risk based on profiling with common genetic variants

Mavaddat, N, Pharoah, P D P, Michailidou, K, Tyrer, J, Brook, M N, Bolla, M K, Wang, Q, Dennis, J, Dunning, A M, Shah, M, Luben, R, Brown, J, Bojesen, S E, Nordestgaard, B G, Nielsen, S F, Flyger, H, Czene, K, Darabi, H, Eriksson, M, Peto, J, Dos-Santos-Silva, I, Dudbridge, F, Johnson, N, Schmidt, M K, Broeks, A, Verhoef, S, Rutgers, E J, Swerdlow, A, Ashworth, A, Orr, N, Schoemaker, M J, Figueroa, J, Chanock, S J, Brinton, L, Lissowska, J, Couch, F J, Olson, J E, Vachon, C, Pankratz, V S, Lambrechts, D, Wildiers, H, Van Ongeval, C, Van Limbergen, E, Kristensen, V, Grenaker Alnæs, G, Nord, S, Borresen-Dale, A-L, Nevanlinna, H, Muranen, TA, Aittomäki, K, Blomqvist, C, Chang-Claude, J, Rudolph, A, Seibold, P, Flesch-Janys, D, Fasching, P A, Haeberle, L, Ekici, A B, Beckmann, M W, Burwinkel, B, Marme, F, Schneeweiss, A, Sohn, C, Trentham-Dietz, A, Newcomb, P, Titus, L, Egan, K M, Hunter, D J, Lindstrom, S, Tamimi, R M, Kraft, P, Rahman, N, Turnbull, C, Renwick, A, Seal, S, LI, J, Liu, J, Humphreys, K, Benitez, J, Pilar Zamora, M, Arias Perez, J I, Menéndez, P, Jakubowska, A, Lubinski, J, Jaworska-Bieniek, K, Durda, K, Bogdanova, N V, Antonenkova, N N, Dörk, T, Anton-Culver, H, Neuhausen, S L, Ziogas, A, Bernstein, L, Devilee, P, Tollenaar, R A E M, Seynaeve, C, Van Asperen, C J, Cox, A, Cross, S S, Reed, M, Khusnutdinova, E, Bermisheva, M, Prokofyeva, D, Takhirova, Z, Meindl, A, Schmutzler, R K, Sutter, C, Yang, R, Schürmann, P, Bremer, M, Christiansen, H, Park-Simon, T-W, Hillemanns, P, Guénel, P, Truong, T, Menegaux, F, Sanchez, M, Radice, P, Peterlongo, P, Manoukian, S, Pensotti, V, Hopper, J L, Tsimiklis, H, Apicella, C, Southey, M C, Brauch, H, Brűning, T, Ko, Y-D, Sigurdson, A J, Doody, M M, Hamann, U, Torres, D, Ulmer, H-U, Försti, A, Sawyer, E J, Tomlinson, I, Kerin, M J, Miller, N, Andrulis, I L, Knight, J A, Glendon, G, Marie Mulligan, A, Chenevix-Trench, G, Balleine, R, Giles, G G, Milne, R L, McLean, C, Lindblom, A, Margolin, S, Haiman, C A, Henderson, B E, Schumacher, F, Le Marchand, L, Eilber, U, Wang-Gohrke, S, Hooning, M J, Hollestelle, A, Van Den Ouweland, A M W, Koppert, L B, Carpenter, J, Clarke, C, Scott, R, Mannermaa, A, Kataja, V, Kosma, V-M, Hartikainen, J M, Brenner, H, Arndt, V, Stegmaier, C, Karina Dieffenbach, A, Winqvist, R, Pylkäs, K, Jukkola-Vuorinen, A, Grip, M, Offit, K, Vijai, J, Robson, M, Rau-Murthy, R, Dwek, M, Swann, R, Annie Perkins, K, Goldberg, M S, Labrèche, F, Dumont, M., Eccles, D M, Tapper, W J, Rafiq, S, John, E M, Whittemore, A S, Slager, S, Yannoukakos, D, Toland, A E, Yao, S, Zheng, W, Halverson, S L, González-Neira, A, Pita, G, Rosario Alonso, M, Álvarez, N, Herrero, D, Tessier, D C, Vincent, D, Bacot, F, Luccarini, C, Baynes, C, Ahmed, S, Maranian, M, Healey, C S, Simard, J, Hall, P, Easton, D F and Garcia-Closas, M (2015) Prediction of breast cancer risk based on profiling with common genetic variants. Journal of the National Cancer Institute, 107 (5). djv036. ISSN 0027-8874

[img] PDF - Published Version
Available under License Creative Commons Attribution.

Download (5MB)


Background: Data for multiple common susceptibility alleles for breast cancer may be combined to identify women at different levels of breast cancer risk. Such stratification could guide preventive and screening strategies. However, empirical evidence for genetic risk stratification is lacking. Methods: We investigated the value of using 77 breast cancer-associated single nucleotide polymorphisms (SNPs) for risk stratification, in a study of 33 673 breast cancer cases and 33 381 control women of European origin. We tested all possible pair-wise multiplicative interactions and constructed a 77-SNP polygenic risk score (PRS) for breast cancer overall and by estrogen receptor (ER) status. Absolute risks of breast cancer by PRS were derived from relative risk estimates and UK incidence and mortality rates. Results: There was no strong evidence for departure from a multiplicative model for any SNP pair. Women in the highest 1 of the PRS had a three-fold increased risk of developing breast cancer compared with women in the middle quintile (odds ratio [OR] = 3.36, 95% confidence interval [CI] = 2.95 to 3.83). The ORs for ER-positive and ER-negative disease were 3.73 (95% CI = 3.24 to 4.30) and 2.80 (95% CI = 2.26 to 3.46), respectively. Lifetime risk of breast cancer for women in the lowest and highest quintiles of the PRS were 5.2% and 16.6% for a woman without family history, and 8.6% and 24.4% for a woman with a first-degree family history of breast cancer. Conclusions: The PRS stratifies breast cancer risk in women both with and without a family history of breast cancer. The observed level of risk discrimination could inform targeted screening and prevention strategies. Further discrimination may be achievable through combining the PRS with lifestyle/environmental factors, although these were not considered in this report. © 2015 © The Author 2015. Published by Oxford University Press.

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Brighton and Sussex Medical School
Depositing User: Esme Acton-Stewart
Date Deposited: 18 Mar 2016 14:46
Last Modified: 02 Jul 2019 18:52

View download statistics for this item

📧 Request an update